Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

M Forster; E Felip; B Doger; Antonio López-Pousa; Enric Carcereny; P. Bajaj; Matthew Church; J Peguero; P Roxburgh; F Triebel

doi:10.1016/j.annonc.2020.08.1042

Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2^nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

M Forster, E Felip, B Doger, Antonio López-Pousa, Enric Carcereny, P. Bajaj, Matthew Church, J Peguero, P Roxburgh, F Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	927P
Journal	Annals of Oncology
Volume	31
Issue number	Supplement 4
DOIs	https://doi.org/10.1016/j.annonc.2020.08.1042
Publication status	Published - 1 Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2020.08.1042

Cite this

Forster, M., Felip, E., Doger, B., López-Pousa, A., Carcereny, E., Bajaj, P., Church, M., Peguero, J., Roxburgh, P., & Triebel, F. (2020). Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2^nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. Annals of Oncology, 31(Supplement 4), Article 927P. https://doi.org/10.1016/j.annonc.2020.08.1042

@article{69004251e25140b4acea23f4443a8c5a,

title = "Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients",

author = "M Forster and E Felip and B Doger and Antonio L{\'o}pez-Pousa and Enric Carcereny and P. Bajaj and Matthew Church and J Peguero and P Roxburgh and F Triebel",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2020.08.1042",

language = "English",

volume = "31",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "Supplement 4",

}

Forster, M, Felip, E, Doger, B, López-Pousa, A, Carcereny, E, Bajaj, P, Church, M, Peguero, J, Roxburgh, P & Triebel, F 2020, 'Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2^nd line treatment for PD-L1 unselected metastatic head and neck cancer patients', Annals of Oncology, vol. 31, no. Supplement 4, 927P. https://doi.org/10.1016/j.annonc.2020.08.1042

Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2^nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. / Forster, M; Felip, E; Doger, B et al.
In: Annals of Oncology, Vol. 31, No. Supplement 4, 927P, 01.09.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

AU - Forster, M

AU - Felip, E

AU - Doger, B

AU - López-Pousa, Antonio

AU - Carcereny, Enric

AU - Bajaj, P.

AU - Church, Matthew

AU - Peguero, J

AU - Roxburgh, P

AU - Triebel, F

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://dx.doi.org/10.1016/j.annonc.2020.08.1042

U2 - 10.1016/j.annonc.2020.08.1042

DO - 10.1016/j.annonc.2020.08.1042

M3 - Article

SN - 0923-7534

VL - 31

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 4

M1 - 927P

ER -

Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

UN SDGs

Access to Document

Other files and links

Cite this

Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2^nd line treatment for PD-L1 unselected metastatic head and neck cancer patients